The Assessment of the Safety, Efficacy, and Practicality of an Algorithm Including Amantadine, Metformin and Zonisamide for the Prevention of Olanzapine-Associated Weight Gain in Outpatients With Schizophrenia.
Phase of Trial: Phase III
Latest Information Update: 06 Oct 2009
At a glance
- Drugs Amantadine; Metformin; Zonisamide
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 31 Aug 2018 Biomarkers information updated
- 05 Nov 2008 Status changed from active, no longer recruiting to completed.
- 28 Sep 2008 Planned end date changed from 1 Dec 2008 to 1 Sep 2008 according to the ClinicalTrials.gov record.